CD33 and acute myeloid leukemia: In the context of MRD, current lines of investigation to eliminate MDSCs are firstly the CD33 targeted antibody-conjugate gemtuzumab ozogamicin is approved for use in patients with CD33+ acute myeloid leukaemia.